Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Controlling escape from angiogenesis inhibitors.

Sennino B, McDonald DM.

Nat Rev Cancer. 2012 Oct;12(10):699-709. doi: 10.1038/nrc3366. Review.

2.

The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.

Li C, Liu T, Bazhin AV, Yang Y.

J Cell Physiol. 2017 Sep;232(9):2312-2322. doi: 10.1002/jcp.25726. Epub 2017 Apr 10. Review.

PMID:
27935039
3.

Vascular endothelial growth factor as a therapeutic target in cancer.

Bergsland EK.

Am J Health Syst Pharm. 2004 Nov 1;61(21 Suppl 5):S4-11. Review.

PMID:
15552621
4.

Mechanisms of drug resistance to vascular endothelial growth factor (VEGF) inhibitors.

Tavakoli J, Aragon-Ching JB.

Anticancer Agents Med Chem. 2010 Oct 1;10(8):593-600. Review.

PMID:
21182470
5.

Recent advances in angiogenesis, anti-angiogenesis and vascular targeting.

Bikfalvi A, Bicknell R.

Trends Pharmacol Sci. 2002 Dec;23(12):576-82. Review.

PMID:
12457776
6.

The VEGF pathway in cancer and disease: responses, resistance, and the path forward.

Kieran MW, Kalluri R, Cho YJ.

Cold Spring Harb Perspect Med. 2012 Dec 1;2(12):a006593. doi: 10.1101/cshperspect.a006593. Review.

7.

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.

Shojaei F, Ferrara N.

Drug Resist Updat. 2008 Dec;11(6):219-30. doi: 10.1016/j.drup.2008.09.001. Epub 2008 Oct 23. Review.

PMID:
18948057
8.

Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.

Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM.

Cancer Res. 2004 May 15;64(10):3586-92.

9.

[VEGF, anti-vEGF and diseases].

Corvol P.

Bull Acad Natl Med. 2008 Feb;192(2):289-300; discussion 300-2. Review. French.

PMID:
18819684
10.

Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.

Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, Yoon SS.

Clin Cancer Res. 2008 Mar 1;14(5):1529-39. doi: 10.1158/1078-0432.CCR-07-4126.

11.

LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.

Chung SW, Bae SM, Lee M, Al-Hilal TA, Lee CK, Kim JK, Kim IS, Kim SY, Byun Y.

Biomaterials. 2015 Jan;37:271-8. doi: 10.1016/j.biomaterials.2014.10.004. Epub 2014 Oct 28.

PMID:
25453957
12.

Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.

De Bock K, Cauwenberghs S, Carmeliet P.

Curr Opin Genet Dev. 2011 Feb;21(1):73-9. doi: 10.1016/j.gde.2010.10.008. Epub 2010 Nov 22. Review.

PMID:
21106363
13.

Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha.

Oh SH, Woo JK, Jin Q, Kang HJ, Jeong JW, Kim KW, Hong WK, Lee HY.

Int J Cancer. 2008 Jan 1;122(1):5-14.

14.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
15.

Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.

Bertolini F, Marighetti P, Martin-Padura I, Mancuso P, Hu-Lowe DD, Shaked Y, D'Onofrio A.

Drug Discov Today. 2011 Dec;16(23-24):1052-60. doi: 10.1016/j.drudis.2011.08.007. Epub 2011 Aug 22. Review.

PMID:
21875682
16.

Mechanisms of resistance to antiangiogenesis therapy.

Azam F, Mehta S, Harris AL.

Eur J Cancer. 2010 May;46(8):1323-32. doi: 10.1016/j.ejca.2010.02.020. Epub 2010 Mar 17. Review.

PMID:
20236818
17.

The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.

Moens S, Goveia J, Stapor PC, Cantelmo AR, Carmeliet P.

Cytokine Growth Factor Rev. 2014 Aug;25(4):473-82. doi: 10.1016/j.cytogfr.2014.07.009. Epub 2014 Jul 23. Review.

PMID:
25169850
18.

Hypoxia inducible factor-1 independent pathways in tumor angiogenesis.

Mizukami Y, Kohgo Y, Chung DC.

Clin Cancer Res. 2007 Oct 1;13(19):5670-4. Review.

19.

Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.

Bottsford-Miller JN, Coleman RL, Sood AK.

J Clin Oncol. 2012 Nov 10;30(32):4026-34. doi: 10.1200/JCO.2012.41.9242. Epub 2012 Sep 24. Review. Erratum in: J Clin Oncol. 2013 Feb 20;31(6):824.

20.

Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity.

Kelly RJ, Darnell C, Rixe O.

Cancer J. 2010 Nov-Dec;16(6):635-42. doi: 10.1097/PPO.0b013e3181ff37cf. Review.

PMID:
21131797

Supplemental Content

Support Center